Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6841 to 6855 of 7680 results

  1. Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

    Discontinued [GID-TA10635]

  2. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued [GID-TA10539]

  3. Skin abscess: antimicrobial prescribing

    Discontinued [GID-NG10163]

  4. Blepharitis: antimicrobial prescribing

    Discontinued [GID-NG10168]

  5. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

  6. Bavituximab for treating non-squamous non-small-cell lung cancer after platinum-based chemotherapy [ID975]

    Discontinued [GID-TA11260]

  7. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

  8. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued [GID-TA11262]

  9. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued [GID-TA10259]

  10. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued [GID-TAG408]

  11. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued [GID-TAG385]

  12. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development [GID-TA10575] Expected publication date: TBC